Meitav Dash Investments Ltd. lowered its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) by 0.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,720 shares of the financial services provider’s stock after selling 218 shares during the period. Meitav Dash Investments Ltd.’s holdings in iShares Biotechnology ETF were worth $4,002,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in IBB. Mascoma Wealth Management LLC lifted its stake in iShares Biotechnology ETF by 10.1% in the first quarter. Mascoma Wealth Management LLC now owns 1,127 shares of the financial services provider’s stock worth $147,000 after acquiring an additional 103 shares during the period. Procyon Advisors LLC lifted its stake in iShares Biotechnology ETF by 23.2% in the first quarter. Procyon Advisors LLC now owns 3,243 shares of the financial services provider’s stock worth $423,000 after acquiring an additional 610 shares during the period. HM Payson & Co. lifted its stake in iShares Biotechnology ETF by 430.0% in the fourth quarter. HM Payson & Co. now owns 1,235 shares of the financial services provider’s stock worth $188,000 after acquiring an additional 1,002 shares during the period. Benjamin Edwards Inc. lifted its stake in iShares Biotechnology ETF by 16.9% in the fourth quarter. Benjamin Edwards Inc. now owns 1,044 shares of the financial services provider’s stock worth $159,000 after acquiring an additional 151 shares during the period. Finally, G&S Capital LLC purchased a new stake in iShares Biotechnology ETF in the first quarter worth about $3,980,000. 63.88% of the stock is currently owned by institutional investors.
iShares Biotechnology ETF Stock Up 1.0 %
NASDAQ:IBB opened at $131.44 on Friday. iShares Biotechnology ETF has a 1-year low of $104.29 and a 1-year high of $177.37. The company has a 50-day moving average of $119.28 and a 200 day moving average of $122.98.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
- Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.